Evaluation of anti-Wnt/β-catenin signaling agents by pGL4-TOP transfected stable cells with a luciferase reporter system

Brazilian Journal of Medical and Biological Research

Volumn 43, Issue 10, 2010, Pages 931-941

  Chuang, K A ^a   Lieu, C H ^a   Tsai, W J ^b,c   Wu, M H ^a   Chen, Y C ^a   Liao, J F ^a   Wang, C C ^d   Kuo, Y C ^e  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b NATIONAL RESEARCH INSTITUTE OF CHINESE MEDICINE   (Taiwan)

^c Institute of Life Science   (Taiwan)

^d FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^e FU JEN CATHOLIC UNIVERSITY   (Taiwan)

Author keywords

Cancer; Plasmids; Reporter assay; Screening; Wnt; catenin

Indexed keywords

6 BROMOINDIRUBIN 3' OXIME; ACETYLSALICYLIC ACID; BETA CATENIN; ENZYME INHIBITOR; HYGROMYCIN B; LITHIUM CHLORIDE; LUCIFERASE; NORCANTHARIDIN; RECOMBINANT PROTEIN; THYMIDINE; UNCLASSIFIED DRUG; WNT PROTEIN; WNT3A PROTEIN;

ARTICLE; BINDING SITE; CELL PROLIFERATION; CLONE; CONCENTRATION RESPONSE; EMBRYO; ENZYME ACTIVITY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PLASMID; SCREENING; WESTERN BLOTTING;

EID: 78149272917     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2010007500091     Document Type: Article

References (32)

1. Ysebaert L, Chicanne G, Demur C, De Toni F, Prade-Houd-ellier N, Ruidavets JB, et al. Expression of beta-catenin by acute myeloid leukemia cells predicts enhanced clonogenic capacities and poor prognosis. Leukemia 2006; 20: 1211-1216.
2. Groen RW, Oud ME, Schilder-Tol EJ, Overdijk MB, ten Berge D, Nusse R, et al. Illegitimate WNT pathway activation by beta-catenin mutation or autocrine stimulation in T-cell malignancies. Cancer Res 2008; 68: 6969-6977.
3. Simon M, Grandage VL, Linch DC, Khwaja A. Constitutive activation of the Wnt/beta-catenin signalling pathway in acute myeloid leukaemia. Oncogene 2005; 24: 2410-2420.
4. Ishii H, Iwatsuki M, Ieta K, Ohta D, Haraguchi N, Mimori K, et al. Cancer stem cells and chemoradiation resistance. Cancer Sci 2008; 99: 1871-1877.
5. Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004; 351: 657-667.
6. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, et al. Identifcation of pancreatic cancer stem cells. Cancer Res 2007; 67: 1030-1037.
7. Malanchi I, Peinado H, Kassen D, Hussenet T, Metzger D, Chambon P, et al. Cutaneous cancer stem cell maintenance is dependent on beta-catenin signalling. Nature 2008; 452: 650-653.
8. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immuno-defcient mice. Nature 2007; 445: 106-110.
9. Dihlmann S, Klein S, Doeberitz Mv MK. Reduction of beta-catenin/T-cell transcription factor signaling by aspirin and indomethacin is caused by an increased stabilization of phosphorylated beta-catenin. Mol Cancer Ther 2003; 2: 509-516.
10. Lepourcelet M, Chen YN, France DS, Wang H, Crews P, Petersen F, et al. Small-molecule antagonists of the onco-genic Tcf/beta-catenin protein complex. Cancer Cell 2004; 5: 91-102.
11. Emami KH, Nguyen C, Ma H, Kim DH, Jeong KW, Eguchi M, et al. A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected]. Proc Natl Acad Sci U S A 2004; 101: 12682-12687.
12. Brembeck FH, Rosario M, Birchmeier W. Balancing cell adhesion and Wnt signaling, the key role of beta-catenin. Curr Opin Genet Dev 2006; 16: 51-59.
13. Kikuchi A, Kishida S, Yamamoto H. Regulation of Wnt signaling by protein-protein interaction and post-translational modifcations. Exp Mol Med 2006; 38: 1-10.
14. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, et al. Identifcation of c-MYC as a target of the APC pathway. Science 1998; 281: 1509-1512.
15. Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999; 398: 422-426.
16. Chen YC, Chang SC, Wu MH, Chuang KA, Wu JY, Tsai WJ, et al. Norcantharidin reduced cyclins and cytokines production in human peripheral blood mononuclear cells. Life Sci 2009; 84: 218-226.
17. Barolo S. Transgenic Wnt/TCF pathway reporters: all you need is Lef? Oncogene 2006; 25: 7505-7511.
18. Hedgepeth CM, Conrad LJ, Zhang J, Huang HC, Lee VM, Klein PS. Activation of the Wnt signaling pathway: a molecular mechanism for lithium action. Dev Biol 1997; 185: 82-91.
19. Cho M, Gwak J, Park S, Won J, Kim DE, Yea SS, et al. Diclofenac attenuates Wnt/beta-catenin signaling in colon cancer cells by activation of NF-kappaB. FEBS Lett 2005; 579: 4213-4218.
20. Chung EJ, Hwang SG, Nguyen P, Lee S, Kim JS, Kim JW, et al. Regulation of leukemic cell adhesion, proliferation, and survival by beta-catenin. Blood 2002; 100: 982-990.
21. Janssens N, Janicot M, Perera T. The Wnt-dependent signaling pathways as target in oncology drug discovery. Invest New Drugs 2006; 24: 263-280.
22. Park S, Gwak J, Cho M, Song T, Won J, Kim DE, et al. Hexachlorophene inhibits Wnt/beta-catenin pathway by promoting Siah-mediated beta-catenin degradation. Mol Pharmacol 2006; 70: 960-966.
23. Suzuki A, Ozono K, Kubota T, Kondou H, Tachikawa K, Mich-igami T. PTH/cAMP/PKA signaling facilitates canonical Wnt signaling via inactivation of glycogen synthase kinase-3beta in osteoblastic Saos-2 cells. J Cell Biochem 2008; 104: 304-317.
24. Kirschner LS. De novo generation of simple sequence during gene amplifcation. Nucleic Acids Res 1996; 24: 2829-2834.
25. Binnerts ME, Kim KA, Bright JM, Patel SM, Tran K, Zhou M, et al. R-Spondin1 regulates Wnt signaling by inhibiting internalization of LRP6. Proc Natl Acad Sci U S A 2007; 104: 14700-14705.
26. Meijer L, Skaltsounis AL, Magiatis P, Polychronopoulos P, Knockaert M, Leost M, et al. GSK-3-selective inhibitors derived from Tyrian purple indirubins. Chem Biol 2003; 10: 1255-1266.
27. Efferth T, Li PC, Konkimalla VS, Kaina B. From traditional Chinese medicine to rational cancer therapy. Trends Mol Med 2007; 13: 353-361.
28. Tsauer W, Lin JG, Lin PY, Hsu FL, Chiang HC. The effects of cantharidin analogues on xanthine oxidase. Anticancer Res 1997; 17: 2095-2098.
29. Liao HF, Su SL, Chen YJ, Chou CH, Kuo CD. Norcantharidin preferentially induces apoptosis in human leukemic Jurkat cells without affecting viability of normal blood mononuclear cells. Food Chem Toxicol 2007; 45: 1678-1687.
30. Huang Y, Liu Q, Liu K, Yagasaki K, Zhang G. Suppression of growth of highly-metastatic human breast cancer cells by norcantharidin and its mechanisms of action. Cytotechnol-ogy 2009; 59: 201-208.
31. Hart ME, Chamberlin AR, Walkom C, Sakoff JA, McClus-key A. Modifed norcantharidins; synthesis, protein phos-phatases 1 and 2A inhibition, and anticancer activity. Bioorg Med Chem Lett 2004; 14: 1969-1973.
32. Eichhorn PJ, Creyghton M P, Bernards R. Protein phos-phatase 2A regulatory subunits and cancer. Biochim Biophys Acta 2009; 1795: 1-15.